It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
Filing for WHO Emergency Use Authorisation this month
Advances deployment of mRNA technology across vaccines and therapeutics development
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
He will be stationed at the company HQ in Bengaluru, India
Dr.Reddy's will receive U.S. $6 million upfront upon closing followed by U.S. $9 million one year from closing
Deal for 100 million doses with additional 100 million through 2023
_logo_256_384.jpg){kind=logo}
It supports sequencing-based COVID 19 surveillance in India
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
Acquisition of A&C expands Aceto’s Western manufacturing footprint
Subscribe To Our Newsletter & Stay Updated
